Management of Isolated Systolic Hypertension

First‑Line Monotherapy (Canadian Hypertension Education Program)

Thiazide or thiazide‑like diuretics (chlorthalidone, indapamide) are Grade A first‑line agents for isolated systolic hypertension; chlorthalidone and indapamide are preferred over hydrochlorothiazide because of their longer duration of action. 1
Long‑acting dihydropyridine calcium‑channel blockers (amlodipine, nifedipine) are Grade A first‑line agents for isolated systolic hypertension. [1][2]3
Angiotensin‑receptor blockers (ARBs) are Grade B first‑line agents for isolated systolic hypertension. [1][2]3
Dihydropyridine CCBs lower peripheral vascular resistance without compromising cardiac output, providing effective systolic pressure reduction. (European Society of Cardiology) 4

Beta‑blockers are contraindicated as first‑line therapy in patients ≥ 60 years with isolated systolic hypertension (Grade A recommendation against) because they are less effective at reducing stroke and provide inferior cardiovascular protection compared with thiazides and CCBs. [1][2][3][5]6
Alpha‑blockers are not recommended for uncomplicated isolated systolic hypertension (Grade A recommendation against). [1][2]3
ACE inhibitors are not first‑line unless a compelling indication exists (e.g., chronic kidney disease, diabetes with albuminuria). [1][5]

Begin two‑drug combination therapy when systolic BP is ≥20 mmHg above target (typically ≥160 mmHg). [1][4]
Preferred Grade A combination: ARB + long‑acting dihydropyridine CCB. (ESC) 4
Grade B combination: thiazide‑type diuretic + long‑acting dihydropyridine CCB. [1][2]
Single‑pill fixed‑dose combinations are strongly preferred to improve adherence. (ESC) 4

If target systolic < 130 mmHg is not achieved with standard‑dose monotherapy, add a second first‑line agent (Grade B). [1][2]4
If BP remains uncontrolled with two agents, escalate to a three‑drug regimen: ARB (or ACE inhibitor) + dihydropyridine CCB + thiazide diuretic. [1][4]
For resistant hypertension after three drugs, add spironolactone 25 mg daily as a fourth agent. (ESC) 4

Check serum potassium within 7 days of initiating a thiazide diuretic; hypokalemia occurs in ≈10–15 % of patients on chlorthalidone 25 mg daily. 9
Avoid chlorthalidone doses > 12.5 mg in patients taking SSRIs (e.g., citalopram, escitalopram) because of a marked hyponatremia risk. 9
Reassess blood pressure monthly until the target <130/80 mmHg is reached, then every 3–5 months. 8
If serum creatinine rises >20–30 % within one week of starting therapy, repeat renal function testing and consider dose adjustment. 9

In Black patients with isolated systolic hypertension, thiazide diuretics and dihydropyridine CCBs are more effective than ACE inhibitors or ARBs as monotherapy. 10
ACE inhibitors provide ≈51 % less stroke risk reduction in Black patients compared with dihydropyridine CCBs. 10

Do not combine an ACE inhibitor with an ARB (Grade A recommendation against) because of increased hyperkalemia and acute kidney injury risk without additional cardiovascular benefit. [1][2]4
Avoid pairing non‑dihydropyridine CCBs (diltiazem, verapamil) with beta‑blockers due to the risk of severe bradycardia and heart block. [1][9]
Beta‑blockers should not be used as first‑line therapy in patients ≥ 60 years unless a compelling indication exists (e.g., post‑MI, heart failure, angina). [1][2][3][5]6

Most patients require 2–3 antihypertensive agents to achieve target BP; do not persist with ineffective monotherapy beyond 4 weeks. 8